In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol

被引:65
作者
Ammons, Mary Cloud B. [1 ]
Ward, Loren S. [2 ]
Fisher, Steve T. [1 ]
Wolcott, Randall D. [3 ]
James, Garth A. [1 ]
机构
[1] Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA
[2] Glanbia Res & Dev Ctr, Twin Falls, ID 83301 USA
[3] SW Reg Wound Care Ctr, Med Biofilm Res Inst, Lubbock, TX 79410 USA
关键词
Pseudomonas aeruginosa; Biofilm; Lactoferrin; Xylitol; BACTERIAL BIOFILMS; ESCHERICHIA-COLI; LIPOPOLYSACCHARIDE; SURVIVAL; MUTANS; GROWTH; CELLS;
D O I
10.1016/j.ijantimicag.2008.08.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The medical impact of bacterial biofilms has increased with the recognition of biofilms as a major contributor to chronic wounds such as diabetic foot ulcers, venous leg ulcers and pressure ulcers. Traditional methods of treatment have proven ineffective, therefore this article presents in vitro evidence to support the use of novel antimicrobials in the treatment of Pseudomonas aeruginosa biofilm. An in vitro biofilm model with a clinical isolate of P. aeruginosa was subjected to treatment with either lactoferrin or xylitol alone or in combination. Combined lactoferrin and xylitol treatment disrupted the structure of the P. aeruginosa biofilm and resulted in a >2log reduction in viability. In situ analysis indicated that while xylitol treatment appeared to disrupt the biofilm structure, lactoferrin treatment resulted in a greater than two-fold increase in the number of permeabilised bacterial cells. The findings presented here indicated that combined treatment with lactoferrin and xylitol significantly decreases the viability of established P. aeruginosa biofilms in vitro and that the antimicrobial mechanism of this treatment includes both biofilm structural disruption and permeablisation of bacterial membranes. Published by Elsevier B. V. on behalf of International Society of Chemotherapy
引用
收藏
页码:230 / 236
页数:7
相关论文
共 46 条
[1]   Why chronic wounds will not heal: a novel hypothesis [J].
Bjarnsholt, Thomas ;
Kirketerp-Moller, Klaus ;
Jensen, Peter Ostrup ;
Madsen, Kit G. ;
Phipps, Richard ;
Krogfelt, Karen ;
Hoiby, Niels ;
Givskov, Michael .
WOUND REPAIR AND REGENERATION, 2008, 16 (01) :2-10
[2]   BIOFILMS AND THEIR CONSEQUENCES, WITH PARTICULAR REFERENCE TO HYGIENE IN THE FOOD-INDUSTRY [J].
CARPENTIER, B ;
CERF, O .
JOURNAL OF APPLIED BACTERIOLOGY, 1993, 75 (06) :499-511
[3]   The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].
Ceri, H ;
Olson, ME ;
Stremick, C ;
Read, RR ;
Morck, D ;
Buret, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776
[4]   INTERACTION OF LACTOFERRIN AND LIPOPOLYSACCHARIDE (LPS) - EFFECTS ON THE ANTIOXIDANT PROPERTY OF LACTOFERRIN AND THE ABILITY OF LPS TO PRIME HUMAN NEUTROPHILS FOR ENHANCED SUPEROXIDE FORMATION [J].
COHEN, MS ;
MAO, JH ;
RASMUSSEN, GT ;
SERODY, JS ;
BRITIGAN, BE .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1375-1378
[5]   Bacterial biofilms: A common cause of persistent infections [J].
Costerton, JW ;
Stewart, PS ;
Greenberg, EP .
SCIENCE, 1999, 284 (5418) :1318-1322
[6]   Effect of lactoferrin on Helicobacter felis induced gastritis [J].
Dial, EJ ;
Lichtenberger, LM .
BIOCHEMISTRY AND CELL BIOLOGY, 2002, 80 (01) :113-117
[7]   ANTIBODIES TO ESCHERICHIA-COLI O-ANTIGENS AND THE INVITRO BACTERIOSTATIC PROPERTIES OF HUMAN-MILK AND ITS IGA [J].
DOLBY, JM ;
STEPHENS, S .
ACTA PAEDIATRICA SCANDINAVICA, 1983, 72 (04) :577-582
[8]   Biofilms: Survival mechanisms of clinically relevant microorganisms [J].
Donlan, RM ;
Costerton, JW .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :167-+
[9]  
Dowd SE, 2008, BMC MICROBIOL, V8, DOI [10.1186/1471-2180-8-125, 10.1186/1471-2180-8-43]
[10]   Bacterial adhesion: Seen any good biofilms lately? [J].
Dunne, WM .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :155-+